Drug Trial Radar · NCT04138277
A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Dec 18, 2019
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, international open-label extension study of ATB200/AT2221 in adult subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
Conditions
- Pompe Disease (Late-onset)
Interventions
AT2221Drug
Participants received ATB200 co-administered with AT2221 (miglustat)
ATB200Biological
Enzyme Replacement Therapy via intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs Leading to Discontinuation of Study DrugTime frame: Entire extension study (mean = 40.5 months on treatment)
Locations
60 sites in 23 countries. Site status is shown where the registry gives one.
University of Arkansas for Medical Sciences
Little Rock, Arkansas
University of California, Irvine
Irvine, California
University of Florida Clinical Research Center
Gainesville, Florida
Emory Clinic
Atlanta, Georgia
IU Health Neuroscience Center
Indianapolis, Indiana
Washington University School of Medicine
St Louis, Missouri
Billings Clinic
Billings, Montana
Hackensack University Medical Center
Hackensack, New Jersey
Northwell Health
Great Neck, New York
NYU School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio
Cincinnati Children's Hospital
Cincinnati, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Montefiore Clinical and Translational Research Center
Pittsburgh, Pennsylvania
University of Utah
Salt Lake City, Utah
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia
Hospital Universitario Austral
Buenos Aires, Argentina
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane & Women's Hospital
Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Medizinische Universität Innsbruck
Innsbruck, Austria
UZ Leuven
Leuven, Belgium
University Clinical Centre of the Republic of Srpska
Banja Luka, The Republic of Srpska, Bosnia and Herzegovina
Alberta Children's Hospital, Heritage Medical Research Clinic
Calgary, Alberta, Canada
McMaster University Medical Centre
Hamilton, Ontario, Canada
Aarhus Universitetshospital
Aarhus, Denmark
Hôpital Pierre Wertheimer
Bron, France
Hôpital Raymond Poincaré
Garches, France
Hôpital Salengro
Lille, France
Hôpital de la Timone
Marseille, France
Hôpital Pasteur 2
Nice, France
Universitätsklinikum Bonn
Bonn, Germany
Friedrich-Baur Institut
München, Germany
Universitätsklinikum Münster
Münster, Germany
Eginition Hospital
Athens, Greece
Semmelweis University
Budapest, Hungary
University of Pécs
Pécs, Hungary
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.